DXR Overview

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Wall Street analysts forecast DXR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Daxor Corp revenue for the last quarter amounts to NaN USD, decreased

Daxor Corp. EPS for the last quarter amounts to USD, decreased

Daxor Corp (DXR) has 750 emplpoyees as of March 31 2026.

Today DXR has the market capitalization of 57.26M USD.